Key Insights

Highlights

Success Rate

65% trial completion

Published Results

20 trials with published results (22%)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 59/100

Termination Rate

20.0%

18 terminated out of 90 trials

Success Rate

65.4%

-21.1% vs benchmark

Late-Stage Pipeline

3%

3 trials in Phase 3/4

Results Transparency

59%

20 of 34 completed with results

Key Signals

20 with results65% success18 terminated

Data Visualizations

Phase Distribution

70Total
Not Applicable (18)
P 1 (26)
P 2 (23)
P 4 (3)

Trial Status

Completed34
Terminated18
Recruiting15
Unknown11
Active Not Recruiting5
Withdrawn4

Trial Success Rate

65.4%

Benchmark: 86.5%

Based on 34 completed trials

Clinical Trials (90)

Showing 20 of 20 trials
NCT06239194Phase 1Recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT02838836Recruiting

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

NCT07227012Phase 1Recruiting

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

NCT02954094Active Not RecruitingPrimary

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

NCT06362369Phase 1Recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT04620538Completed

Volatile Organic Compounds for the Assessment of Liver Disease

NCT06858813Phase 1RecruitingPrimary

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

NCT03937830Phase 2Active Not RecruitingPrimary

Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

NCT05003895Phase 1Recruiting

GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies

NCT03151213Phase 4CompletedPrimary

Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver

NCT05438420Phase 1Active Not Recruiting

Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

NCT03785210Phase 2Terminated

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

NCT05489250TerminatedPrimary

The PLATON Network

NCT07110233Not ApplicableNot Yet Recruiting

Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma

NCT05070247Phase 1Terminated

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

NCT05100082CompletedPrimary

Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma

NCT05064553Active Not Recruiting

ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk

NCT05293496Phase 1Completed

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

NCT03551951Recruiting

Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow

NCT04912765Phase 2Recruiting

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

Scroll to load more

Research Network

Activity Timeline